Stroke Homecare and Recurrence Prevention
Launched by PEKING UNION MEDICAL COLLEGE · Feb 4, 2025
Trial Information
Current as of August 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The "Stroke Homecare and Recurrence Prevention" trial is studying how a new approach called home-based health care (HBHC) can help stroke patients. This program aims to reduce the chances of having another stroke while also improving patients' overall quality of life, physical abilities, and mental health. The trial will involve about 1,614 stroke patients in China who will be randomly assigned to either receive the HBHC program or standard post-stroke care. The HBHC program includes support for managing health risks, rehabilitation, daily living skills, nutritional advice, and psychological help over 12 months.
To participate in this trial, you must be an adult aged 18 or older who has had a stroke within the last month and is in stable condition ready to go home. You also need to be able to receive care at home and live in an area where this service is available. However, if you have been receiving care at a rehabilitation center for over a month, have severe health issues, or are participating in another clinical trial, you may not be eligible. Throughout the study, participants will be followed up at 6 and 12 months to see how they are doing and to evaluate the effectiveness of the HBHC program. This research aims to provide valuable insights that could improve stroke care and support better health outcomes for patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18 years and older
- • Diagnosed with ischemic or hemorrhagic stroke within the past month
- • Clinically stable, having completed acute phase treatment, and about to be discharged in a normal condition
- • Physically able to receive home-based health care services
- • Residing in a community where home-based health care is available
- • Able to provide informed consent or have a legally authorized representative provide consent
- Exclusion Criteria:
- • Receiving more than one month of post-discharge care at a stroke rehabilitation center or community rehabilitation center
- • Severe comorbidities (e.g., cancer, respiratory failure, severe infections) with a life expectancy of less than 6 months
- • Severe cognitive impairment or mental illness affecting adherence to the intervention
- • Currently participating in another clinical trial
About Peking Union Medical College
Peking Union Medical College (PUMC) is a prestigious institution renowned for its commitment to advancing medical education, research, and healthcare in China and beyond. As a leading clinical trial sponsor, PUMC excels in designing and conducting rigorous clinical studies that contribute to the development of innovative therapies and medical practices. With a multidisciplinary approach, PUMC leverages its extensive network of healthcare professionals and researchers to ensure high standards of ethical conduct, scientific integrity, and patient safety in all its clinical trials. Through its dedication to fostering collaboration and translating research findings into clinical applications, PUMC plays a pivotal role in enhancing global health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported